Ken Griffin Theravance Biopharma, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 200 shares of TBPH stock, worth $1,918. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200

Previous 13,900 98.56%

Holding current value

$1,918

Previous $117,000 99.15%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$7.66 - $10.25 $72,448 - $96,944	-9,458 Reduced 3.88%	234,556 $1.89 Million
Q2 2024 Aug 14, 2024	BUY	$8.29 - $9.92 $1.06 Million - $1.27 Million	128,206 Added 110.71%	244,014 $2.07 Million
Q1 2024 May 15, 2024	SELL	$8.22 - $11.59 $282,061 - $397,699	-34,314 Reduced 22.86%	115,808 $1.04 Million
Q4 2023 Feb 14, 2024	BUY	$8.58 - $11.4 $972,997 - $1.29 Million	113,403 Added 308.84%	150,122 $1.69 Million
Q3 2023 Nov 14, 2023	SELL	$8.38 - $10.44 $371,217 - $462,471	-44,298 Reduced 54.68%	36,719 $316,000
Q2 2023 Aug 14, 2023	BUY	$10.16 - $11.92 $156,880 - $184,056	15,441 Added 23.55%	81,017 $838,000
Q1 2023 May 15, 2023	SELL	$9.87 - $11.44 $185,259 - $214,728	-18,770 Reduced 22.25%	65,576 $711,000
Q4 2022 Feb 14, 2023	SELL	$9.65 - $11.34 $1.6 Million - $1.88 Million	-166,101 Reduced 66.32%	84,346 $946,000
Q3 2022 Nov 14, 2022	BUY	$8.39 - $10.22 $1.97 Million - $2.4 Million	234,539 Added 1474.35%	250,447 $2.54 Million
Q2 2022 Aug 15, 2022	SELL	$8.41 - $10.34 $5,340 - $6,565	-635 Reduced 3.84%	15,908 $144,000
Q1 2022 May 16, 2022	BUY	$8.33 - $12.96 $49,122 - $76,425	5,897 Added 55.39%	16,543 $158,000
Q4 2021 Feb 14, 2022	BUY	$7.42 - $11.05 $78,993 - $117,638	10,646 New	10,646 $117,000
Q4 2020 Feb 16, 2021	SELL	$14.89 - $20.16 $2.21 Million - $3 Million	-148,752 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$14.79 - $22.49 $328,766 - $499,930	-22,229 Reduced 13.0%	148,752 $2.2 Million
Q2 2020 Aug 14, 2020	BUY	$20.64 - $30.69 $3.11 Million - $4.62 Million	150,527 Added 735.93%	170,981 $3.59 Million
Q1 2020 May 15, 2020	SELL	$17.84 - $31.21 $16,912 - $29,587	-948 Reduced 4.43%	20,454 $473,000
Q4 2019 Feb 14, 2020	BUY	$16.12 - $25.89 $64,463 - $103,534	3,999 Added 22.98%	21,402 $554,000
Q2 2019 Aug 14, 2019	SELL	$15.6 - $25.15 $1.05 Million - $1.69 Million	-67,338 Reduced 79.46%	17,403 $284,000
Q1 2019 May 15, 2019	BUY	$22.57 - $28.15 $1.23 Million - $1.53 Million	54,460 Added 179.85%	84,741 $0
Q4 2018 Feb 14, 2019	BUY	$22.52 - $35.07 $207,499 - $323,134	9,214 Added 43.74%	30,281 $774,000
Q3 2018 Nov 13, 2018	SELL	$22.83 - $32.67 $267,453 - $382,729	-11,715 Reduced 35.74%	21,067 $0
Q2 2018 Aug 10, 2018	BUY	$22.06 - $25.52 $723,170 - $836,596	32,782 New	32,782 $0

Others Institutions Holding TBPH

# of Institutions

122

Shares Held

47.3M

Call Options Held

200

Put Options Held

12.8K

View Full List

About Theravance Biopharma, Inc.

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

More about TBPH

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account